07.21.14
Headquarters: Leverkusen, Germany
twitter.com/Bayer
www.bayerpharma.com
TOP SELLING DRUGS
The pharma arm of a large, diversified chemical and technology company in Germany, Bayer’s pharmaceutical business is divided into pharmaceutical and consumer healthcare divisions.
Recently, the company extended its reach in the consumer healthcare business by acquiring Merck and Company’s consumer healthcare business assets for $14.2 billion, which include such household names as Claritin. It stands to become the world’s second largest consumer healthcare company.
Last year, the company saw its pharmaceuticals business grow by 3%, driven mainly by emerging market growth, consumer healthcare by 4%, and animal health by 4%.
In its name brand pharma business, Bayer is focusing on oncology, hematology and ophthalmology therapies, as well as on hormonal therapies and contraceptives. The company relies on a network of research partnerships to drive innovation, and also explores synergies between biopharmaceutical research projects involving its human, animal and plant health divisions. Healthcare and crop sciences, for instance, are studying energy metabolism and gene regulation.
The company’s pharmaceuticals division has launched five products recently:
• Xarelto (rivaroxaban), an anti-coagulant that is being developed in a license with Janssen
• Stivarga (regorafenib), an oral multikinase inhibitor treatment for colorectal and gastrointestinal cancers, copromoted by Bayer and Amgen’s Onyx Pharmaceuticals, which provides a foothold in the orphan drugs market.
• Xofigo, a treatment for bone metastases in prostate cancer, based o radium 223 dichloride, jointly developed with Algeta SAS of Norway
• Eyelea (aflibercept), jointly developed with Regeneron, a treatment for various eye diseases that blocks natural growth factor (vascular endothelial growth factor (VEGF), preventing abnormal formation of new blood vessels. It was developed for the treatment of wet age-related macular degeneration and edema
• Riociquat, a treatment for pulmonary hypertension that has been approved in the U.S. and Japan. It is the first member of a new class of vasodilating agents
In other areas, the company is working on cancer stem cell research (rather than stem cell research in general) with OncoMed Pharmaceuticals. It is collaborating on BiTe antibodies with Amgen, mitogen-activated ERK kinase inhibitors with Arden Biosciences, and with the BioInvest International on antibodies, and Broad Institute on oncology gene mutation.
Bayer also has joint research projects in place with Peking and Tsinghua universities in China, and has been involved with Oxford University in the U.K. in R&D involving women’s health. The company is working with Prometheus Labs and Qiagen on diagnostics tools that would be used for personalized medicine therapies.
In antibody drug conjugates (ADCs) for the oncology market, Bayer is currently licensing technology from Seattle Genetics. It is also working with Dimension Therapeutics on new gene therapies, and with Nektar and Novartis on antibiotic
inhalation therapies.
The company set up a CoLaborator incubator in San Francisco two years ago, to fund interesting new product ideas and now plans to establish a second one in Berlin. Bayer also addresses biotech research via its Bayer Technology Services division.
twitter.com/Bayer
www.bayerpharma.com
Headcount: | 56,000 | |
Year Established: | 1971 | |
Pharma Revenues: | $15,326 | 9% |
Total Revenues: | $25,923 | 2% |
Net Income: | $15,326 | 4% |
R&D Budget: | $2,265 | 6% |
TOP SELLING DRUGS
Drug | Indication | 2013 Sales | (+/- %) |
Kogenate | hemophilia | $1,646 | 2% |
Betaferon | multiple sclerosis | $1,422 | -15% |
Xarelto | atrial fibrillation | $1,300 | 195% |
Yasmin | contraception | $1,168 | -18% |
Nexavar | oncology | $1,056 | -3% |
Mirena | women’s health | $985 | 6% |
Adalat | hypertension | $826 | -10% |
Avalox | antibiotic | $583 | -12% |
The pharma arm of a large, diversified chemical and technology company in Germany, Bayer’s pharmaceutical business is divided into pharmaceutical and consumer healthcare divisions.
Recently, the company extended its reach in the consumer healthcare business by acquiring Merck and Company’s consumer healthcare business assets for $14.2 billion, which include such household names as Claritin. It stands to become the world’s second largest consumer healthcare company.
Last year, the company saw its pharmaceuticals business grow by 3%, driven mainly by emerging market growth, consumer healthcare by 4%, and animal health by 4%.
In its name brand pharma business, Bayer is focusing on oncology, hematology and ophthalmology therapies, as well as on hormonal therapies and contraceptives. The company relies on a network of research partnerships to drive innovation, and also explores synergies between biopharmaceutical research projects involving its human, animal and plant health divisions. Healthcare and crop sciences, for instance, are studying energy metabolism and gene regulation.
The company’s pharmaceuticals division has launched five products recently:
• Xarelto (rivaroxaban), an anti-coagulant that is being developed in a license with Janssen
• Stivarga (regorafenib), an oral multikinase inhibitor treatment for colorectal and gastrointestinal cancers, copromoted by Bayer and Amgen’s Onyx Pharmaceuticals, which provides a foothold in the orphan drugs market.
• Xofigo, a treatment for bone metastases in prostate cancer, based o radium 223 dichloride, jointly developed with Algeta SAS of Norway
• Eyelea (aflibercept), jointly developed with Regeneron, a treatment for various eye diseases that blocks natural growth factor (vascular endothelial growth factor (VEGF), preventing abnormal formation of new blood vessels. It was developed for the treatment of wet age-related macular degeneration and edema
• Riociquat, a treatment for pulmonary hypertension that has been approved in the U.S. and Japan. It is the first member of a new class of vasodilating agents
In other areas, the company is working on cancer stem cell research (rather than stem cell research in general) with OncoMed Pharmaceuticals. It is collaborating on BiTe antibodies with Amgen, mitogen-activated ERK kinase inhibitors with Arden Biosciences, and with the BioInvest International on antibodies, and Broad Institute on oncology gene mutation.
Bayer also has joint research projects in place with Peking and Tsinghua universities in China, and has been involved with Oxford University in the U.K. in R&D involving women’s health. The company is working with Prometheus Labs and Qiagen on diagnostics tools that would be used for personalized medicine therapies.
In antibody drug conjugates (ADCs) for the oncology market, Bayer is currently licensing technology from Seattle Genetics. It is also working with Dimension Therapeutics on new gene therapies, and with Nektar and Novartis on antibiotic
inhalation therapies.
The company set up a CoLaborator incubator in San Francisco two years ago, to fund interesting new product ideas and now plans to establish a second one in Berlin. Bayer also addresses biotech research via its Bayer Technology Services division.